Study protocol of a multicenter randomized controlled trial of mindfulness-based cognitive therapy and treatment as usual in bipolar disorder

I. Hanssen 1,2*, M. J. Huijbers 1, M. W. H. Lochmann-van Bennekom 3, E. J. Regeer 4, A. W. M. M. Stevens 5, S. M. A. A. Evers 6, M. Wensing 7, R. W. Kupka 4,8 and A. E. M. Speckens 1,2

Abstract

Background: Despite multiple pharmacological interventions, many people with bipolar disorder (BD) experience substantial residual mood symptoms, even in the absence of severe mood episodes, which have a negative impact on the course of illness and quality of life. Limited data are available on how to optimize treatment for BD, especially for those who suffer from persistent and residual depressive symptoms. Preliminary evidence suggests Mindfulness-Based Cognitive Therapy (MBCT) as a psychological treatment option for BD. This study aims to investigate whether adding MBCT to treatment as usual (TAU) will result in symptomatic and functional improvements in adults with BD compared to TAU alone.

Methods/design: This study is a prospective, evaluator blinded, multicenter, randomized controlled trial of MBCT + TAU and TAU alone in 160 adults with bipolar type I and type II. Assessments will be conducted at baseline (T0), mid-treatment (Tmid), and at 3 (T1), 6 (T2), 9 (T3), 12 (T4), and 15 (T5) months follow-up. Primary outcome is post-treatment severity of depressive symptoms (Inventory of Depressive Symptomatology- Clinician administered). Secondary outcomes are severity of (hypo) manic symptoms, anxiety, relapse rates, overall functioning, positive mental health, and cost-effectiveness. As possible mediators will be assessed rumination of negative affect, dampening and rumination of positive affect, mindfulness skills, and self-compassion.

Discussion: This study will provide valuable insight into the (cost-)effectiveness of MBCT on clinician- and self-rated symptoms of BD, relapse rates, positive mental health, and overall functioning.

Trial registration: NCT03507647. Registered 25th of April 2018.

Keywords: Mindfulness-based cognitive therapy, Bipolar disorder, Randomized controlled trial; study protocol

Background

Bipolar disorder (BD) is a disabling, chronic condition characterized by recurrent (hypo) manic, depressive, and/or mixed episodes, affecting approximately 1.2% of adult men and 1.4% of adult women in the Netherlands [1]. BD belongs to the leading causes of years lost due to disability, and is associated with considerable economic, occupational, and social burden [2–4]. Illness-related disability is mostly accounted for by depressive symptoms and episodes [5, 6]. Similar to individuals with major depression, people with BD demonstrate a tendency to ruminate in response to negative affect [7]. This appears to create a vicious cycle of ruminative thinking, decreased interest and motivation, and a loss of positive affect, resulting in an increase in depressive symptoms. Furthermore, people with BD show a tendency to ruminate in response to positive affect as well [8], which has been found to be correlated with increased (hypo) manic symptoms [9, 10]. Despite multiple
pharmacological options, people with BD experience substantial residual mood symptoms about half the time. Approximately 60% of people with BD relapse in a full-blown mood episode within two years after recovering from a previous mood episode [6, 11–13]. These persistent mood symptoms affect the course of BD and quality of life negatively [14]. Therefore, the management of BD requires additional psychological interventions [15, 16]. However, most psychological interventions used in the treatment of BD, such as Cognitive Behavioral Therapy (CBT), are more effective for people with major depression or in people with BD who suffered less than 12 mood episodes [16–18]. Limited data are available on how to optimize treatment for the whole population of people with BD, especially for those who suffer from persistent and residual mood symptoms.

Mindfulness-based approaches have recently been adopted to the Dutch national guidelines of bipolar disorders, adopting Mindfulness-Based Cognitive Therapy (MBCT) as a psychological treatment option in order to prevent depressive relapse in people with BD [19]. MBCT integrates meditative practices with elements of cognitive therapy and aims toward people developing a capacity to be aware of (distressing) thoughts, feelings, and bodily sensations in a non-judgmental way [20, 21]. MBCT has been shown promising results in a wide range of psychiatric disorders [22], including major depression (e.g. [23, 24]), and a limited effect in anxiety disorders [25]. Even though MBCT was adopted as a treatment option to the Dutch national guidelines of bipolar disorders, evidence about its effectiveness in BD is still scarce. There are a number of small pilot studies showing either reductions in severity of depressive and/or anxiety symptoms [26–28], or no improvement in depressive symptoms [29]. To date, only one randomized controlled trial of MBCT for BD has been conducted in 95 participants [30]. This study of Perich et al. found significant improvements in anxiety symptoms, but not in depressive symptoms after MBCT practices over the course of a 12-month follow-up period. However, they included remitted adults with BD only, which may have limited the possible range of symptom reduction and the clinical representativeness of this study. Furthermore, the dropout rates at 12-month follow-up were high, with almost 65% of participants not completing follow-up measures. The current trial will provide the first high-level evidence of the effectiveness of MBCT in addition to treatment as usual (TAU) compared to TAU alone in euthymic or depressed individuals with BD, by including follow-up assessments up to 12 months after completion of treatment and keeping close track of treatment adherence and occurrence of (serious) adverse reactions.

The primary aim of this study is to compare post-intervention depressive symptom severity after MBCT + TAU and TAU alone. The secondary aims are to investigate whether MBCT is effective in reducing long-term depressive symptoms, and post-treatment and long-term (hypo) manic and anxiety symptom severity, relapse rates, and increasing overall functioning and positive mental health. Previous research has shown that the relationship between mindfulness practice and improvement in psychological symptoms is mediated by mindfulness skills, self-compassion, and rumination [31]. Therefore, it is expected that improvements in severity of depressive symptoms is mediated by mindfulness skills, self-compassion, and rumination of negative affect, and dampening and rumination of positive affect. Moreover, since there is some evidence that certain psychological interventions become less effective for people with BD who experienced 12 or more mood episodes [18], the current trial will investigate whether MBCT will be more effective in people with BD with less than 12 mood episodes compared to people with BD who suffered 12 or more mood episodes. Finally, from a societal perspective, the current study will assess whether implementing MBCT + TAU is cost-effective compared to TAU alone. It is expected that adding MBCT to TAU will result in a reduction of medical and societal costs.

In conclusion, the current study will be the first randomized controlled trial of MBCT for BD in the Netherlands and to the best of our knowledge the second RCT overall, providing high-level evidence of the relative long-term effectiveness of MBCT + TAU versus TAU for adults with BD. It will be offered in a multi-centre setting, using several outcome measures, including cost-effectiveness. If (cost-)effective, MBCT might widen the array of evident psychological interventions for BD.

Methods/design
Study design
This study is a prospective, evaluator blinded, multicenter, randomized controlled trial of MBCT + TAU versus TAU alone. Assessments will be conducted at baseline (T0), mid-treatment (Tmid), and at 3 (T1), 6 (T2), 9 (T3), 12 (T4), and 15 (T5) months follow-up. Participants randomized to the TAU condition will be able to participate in a MBCT intervention after they completed the study (15 months). The study protocol has been approved by the ethical review board CMO Arnhem – Nijmegen and is registered under number NL63319.091.17.

Setting
The MBCT interventions will be provided at the Radboud University Medical Centre in Nijmegen, and at five specialized outpatient clinics for bipolar disorders in the Netherlands, including Altrecht (Utrecht), Pro
Person (Arnhem/Nijmegen/Tiel/Ede); Dimence (Zwolle), PsyQ (Rotterdam) and GGZ Breburg (Tilburg/Breda).

Study population
The study population will consist of adults (18 years or older) with BD. The following inclusion criteria will be applied: 1) a confirmed diagnosis of bipolar I or bipolar II disorder, according to the Diagnostic and Statistical Manual of Mental Disorders – 5th edition (DSM-5) [32] and confirmed by using the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I) [33]; 2) having suffered at least two confirmed lifetime depressive episodes, either current or in (partial) remission at baseline; 3) having suffered at least one mood episode (either depressive and/or (hypo)manic) within the year prior to baseline; and 4) a Young Mania Rating Scale (YMRS) [34] score of 12 or lower. The following exclusion criteria will be applied: 1) insufficient comprehension of the Dutch language; 2) previous participation in an eight-week mindfulness-based intervention; 3) having suffered a manic episode within three months before baseline; 4) a lifetime diagnosis of schizophrenia or schizoaffective disorder, current substance abuse disorder, organic brain syndrome, or antisocial or borderline personality disorder; 5) increased risk of suicide or aggression; 6) additional psychological interventions, such as CBT or trauma therapy, at the time of recruitment, baseline assessment or between T0 and T1; and 6) the presence of a concurrent significant medical condition impeding the ability to participate.

Procedure
Clinicians from the participating outpatient clinics will provide the first screening by selecting patients from their caseload who will most likely meet the in- and exclusion criteria of this study. To minimize the risk of “gatekeeping”, they will be asked to only exclude patients not meeting in- or exclusion criteria and to provide the reasons for exclusion on a form. Subsequently, potentially eligible participants will receive an invitation letter and information leaflet from their attending clinicians, after which they can contact the research team. Participants will be recruited by self-selection as well, for example by media advertisements by the Dutch patient association of adults with BD (Vereniging voor Manisch Depressieven en Betrokkenen). After verbal consent is obtained, participants will be invited for a screening by telephone to assess eligibility. Eligible participants will be invited for a research interview with a trained research assistant, where written informed consent will be obtained. During the research interview, participants will be thoroughly screened for in- and exclusion criteria with use of the SCID-I and YMRS. Subsequently, if participants are still eligible to participate, they will be invited for the baseline assessment, which consists of several clinician administered measures and self-report questionnaires (see Table 2). Blinded assessments of clinician-rated measurements will be obtained by trained research assistants at 3, 6, 9, 12, and 15 months follow-up. The 6, 9, and 12 months follow-up assessments will be conducted by telephone. Self-report questionnaires will be obtained at baseline, four weeks after start of the MBCT intervention (mid-treatment) and at 3, 6, 9, 12, and 15 months follow-up. Figure 1 provides a flowchart of the study procedures from referral to final assessment.

Randomization and blinding
Randomization will be computerized using an Electronic Data Capture (EDC) program (CASTOR: https://www.castoredc.com/). Randomization will be stratified for 1) setting; 2) gender; 3) depression status (current vs. remitted); and 4) bipolar type I or II. In order to ensure balanced groups, we will use block randomization with block sizes of either 2, 4, or 6. Research assistants on site will be blinded for allocation and participants will be asked not to talk about their group allocation during assessments.

Treatment as usual
Usual care of people with BD typically consists of pharmacotherapy (usually provided and monitored by a psychiatrist), and psycho-education and self-management interventions, e.g. maintaining biopsychological rhythm, detection and management of early signs of mood dysregulation, and improving coping skills (usually provided and monitored by a psychiatric nurse) [19]. Because of the clinical representativeness, we will not restrict TAU in any way and, therefore, participants will be allowed to switch, taper or augment their medication. It is expected that a large majority of participants in the current study will receive some form of pharmacotherapy. A careful record of this will be kept in order to examine and control for possible differences between the two groups.

Intervention
The MBCT program developed in the current study is an adaptation of the original MBCT intervention for recurrent depression by Segal, Williams, and Teasdale [20]. The MBCT program was adapted to the needs of people with BD in terms of tailoring psycho-educative elements to BD (e.g. adding information and exercises focusing on mania), implementing more movement exercises, introducing the three-minute breathing space earlier and more often in the program, adding a partner session (session 6), and repeatedly bringing focus to self-care. These adaptations were based on qualitative feedback of 15 individuals with BD who participated in
two consecutive pilot groups of traditional MBCT at the Radboud University Medical Centre (Nijmegen, the Netherlands). These qualitative data, focusing on barriers and facilitators, were collected during two focus groups.

The group-based MBCT program consists of eight weekly 2.5 h sessions, a 6-h silent day between session six and seven, and home assignments to practice both formal (e.g. body scan, sitting meditation) and informal meditative exercises (e.g. mindful routine activity) about 45 min per day. All MBCT interventions will be conducted at the respective mental health sites, with each group consisting of 8–10 participants. Table 1 provides an overview of the MBCT program as applied in the current study.

**Mindfulness teachers**

Each MBCT intervention will be taught by two teachers, of whom at least one will qualify the advanced criteria of the Association of Mindfulness Based Teachers in the Netherlands and Flanders, which are in concordance with the good practice guidelines of the UK Network for Mindfulness-Based Teachers [35]. These criteria include the following: 1) a minimum of 150 h of education in MBSR/MBCT background and theory, training in formal and informal meditative practices, psycho-education and
by the Mindfulness-Based Interventions – phase of the trial. Teacher competency will be assessed will be organized repeatedly during the intervention protocol at the start of the trial. Supervision meetings mindfulness teachers will receive additional training in the study MBCT/MBSR interventions per two years. All mindful-

5) continued training; and 6) giving a minimum of two attended a MBSR/MBCT intervention as a participant; training; 3) minimum of three years of practicing medi-

Table 1 Overview of MBCT sessions

| Theme of session | Mindfulness exercises | Didactic teaching | Homework assignments |
|------------------|-----------------------|------------------|----------------------|
| 1. Automatic pilot | - Raisin exercise<br>- Body scan<br>- Three-minute breathing space | - Bipolar disorder<br>- Rationale for mindfulness | - Body scan<br>- Mindful eating<br>- Mindful routine activity<br>- Three-minute breathing space |
| 2. Dealing with barriers | - Awareness of surroundings<br>- Body scan<br>- Sitting meditation – focus on breath<br>- Three-minute breathing space | - Awareness of pleasant events<br>- Automatic positive thoughts (mania)<br>- Recognition and managing core symptoms of mania | - Body scan<br>- Three-minute breathing space<br>- Mindful routine activity<br>- Pleasant events calendar |
| 3. Mindfulness of the breath | - Sitting meditation – focus on breath and body<br>- Three-minute breathing space<br>- Floor yoga | - Awareness of unpleasant events<br>- Automatic negative thoughts<br>- Recognition and managing core symptoms of depression | - Sitting meditation/ mindful walking/ floor yoga/ body scan<br>- Three-minute breathing space (coping)<br>- Stressful events calendar |
| 4. Staying present | - Sitting meditation – focus on breath, body, sounds, and thoughts<br>- Three-minute breathing space<br>- Mindful walking | - Acceptance<br>- Stress<br>- Helping and non-helping thoughts | - Sitting meditation<br>- Standing yoga<br>- Three-minute breathing space (coping)<br>- Communication events calendar |
| 5. Allowing and letting be | - Sitting meditation – focus on breath, body, sounds, and thoughts<br>- Standing yoga<br>- Three-minute breathing space | - Mindfulness and bipolar disorder<br>- Communication – listening and speaking | - Sitting meditation/ mindful walking/ floor yoga/ body scan<br>- Three-minute breathing space<br>- Creating crisis intervention action plan |
| 6. Mindful communication (partner session) | - Standing yoga<br>- Three-minute breathing space | | |
| Silent day - 6 hours | | | |
| 7. Taking care of yourself | - Sitting meditation – focus on breath, body, sounds, thoughts, emotions, and choiceless awareness | - Recognizing symptoms of relapse<br>- Keeping in balance<br>- Relapse prevention plan | - Sitting meditation/ mindful walking/ floor yoga/ body scan<br>- Three-minute breathing space<br>- Adjusting relapse prevention plan Self-evaluation |
| 8. The rest of your life | - Three-minute breathing space<br>- Body scan<br>- Three-minute breathing space | - Preventing relapse<br>- Maintaining practice<br>- Reflection | |

Table 2 provides an overview of the assessments. The primary outcome measure will be the post-intervention (3 months follow-up) total score on the Inventory of Depressive Symptomatology – Clinician administered (IDS – C), a 30-item clinician administered scale to assess depressive symptom severity [38]. Items are scored on a 0–3 point scale, with total score ranges from 0 to 84 (where < 13 = not depressed, 14–25 = mildly depressed, 26–38 = moderately depressed, 39–48 = markedly depressed, and 49 > severely depressed). The psychometric properties of the IDS-C have been shown inquiry, supervision and teaching a MBSR/MBCT including a reflection report; 2) relevant professional training; 3) minimum of three years of practicing mediation regularly and attending retreats; 4) having attended a MBSR/MBCT intervention as a participant; 5) continued training; and 6) giving a minimum of two MBCT/MBSR interventions per two years. All mindfulness teachers will receive additional training in the study protocol at the start of the trial. Supervision meetings will be organized repeatedly during the intervention phase of the trial. Teacher competency will be assessed by the Mindfulness-Based Interventions – Teacher Assessment Criteria (MBI-TAC) [36]. Videotapes of a random selection of sessions will be assessed by assessors who are familiar with the MBCT program, and are proficient mindfulness teachers themselves (level 5) who have received training in the use of these assessment criteria. An early study of the psychometric properties of the MBI-TAC suggests it has good reliability, face validity, and promising evidence of validity [37].

Outcome measures

Primary outcome measures

Table 2 provides an overview of the assessments. The primary outcome measure will be the post-intervention (3 months follow-up) total score on the Inventory of Depressive Symptomatology – Clinician administered (IDS – C), a 30-item clinician administered scale to assess depressive symptom severity [38]. Items are scored on a 0–3 point scale, with total score ranges from 0 to 84 (where < 13 = not depressed, 14–25 = mildly depressed, 26–38 = moderately depressed, 39–48 = markedly depressed, and 49 > severely depressed). The psychometric properties of the IDS-C have been shown
to be highly acceptable in samples of 544 outpatients with major depression and 402 outpatients with BD [39].

**Secondary outcome measures**

The *Young Mania Rating Scale* (YMRS) [34] will be used to assess (hypo) manic symptom severity. The YMRS is an 11-item clinician administered scale, with a total score range of 0 to 60 (where ≤12 indicates remission, 13–19 = minimal symptoms, 20–25 = mildly manic, 26–37 = moderately manic, and 38–60 = severely manic). The psychometric properties of the YMRS have been shown to be adequate [34].

The *Structured Clinical Interview for DSM-IV Axis I Disorders* (SCID-I) [33] will be used to retrospectively assess the occurrence of depressive and/or (hypo)manic relapses in the past three months at each assessment. The psychometric properties of the Dutch translation of the SCID-I have been shown to be excellent [40].

The *Prospective Life Chart, self-report* [41] will be used for participants to daily document the course and severity of recurrent mood episodes in order to gain more fine-grained information about the severity of (hypo)manic and/or depressive symptoms over time. The psychometric properties of the Life Chart have been shown to be adequate [41].

The *Altman Self-Rating Mania Scale* (ASRM) [42] will be used to assess the presence and severity of (hypo)manic symptoms during the intermediate measurements (4 weeks after start MBCT). The ASRM is a 5-item self-report questionnaire with score ranges from 0 to 20 (where 6 ≥ indicates a high probability of a (hypo)manic condition). The psychometric properties of the ASRM have been shown to be good [42].

The *Quick Inventory of Depressive Symptomatology* (QIDS-SR) [43] will be used to assess depressive symptom severity during the intermediate measurements (4 weeks after start MBCT). The QIDS-SR is a 16-item self-report questionnaire with total score ranges from 0 to 27. The psychometric properties of the QIDS-SR have been shown to be adequate [43].

The *State/Trait Anxiety Inventory* (STAI) [44] will be used to assess severity of anxiety symptoms. The STAI is a 20-item, self-report measure with a total score range of 20 to 80. The psychometric properties of the Dutch translation of the STAI have been shown to be adequate [45].

The *Functioning Assessment Short Test* (FAST) [46] will be used to assess overall functioning. The FAST is a 24-item measure that assesses impairment or disability in six specific areas of functioning, including 1) autonomy; 2) occupational functioning; 3) cognitive functioning; 4) financial issues; 5) interpersonal relationships; and 6) leisure time. Psychometric properties of the FAST and its ability to detect differences between euthymic and acute bipolar patients have been shown to be excellent [46].

The *Mental Health Continuum – Short form* (MHC-SF) [47] will be used to assess emotional, psychological, and social well-being. The MHC-SF is a 14-item measure with a total score range of 0 to 70. The psychometric properties of the MHC-SF have been shown to be adequate [47].

---

**Table 2** Overview of assessments

|                     | T0 (baseline) | Tmid (4 weeks) | T1 (3 months) | T2 (6 months) | T3 (9 months) | T4 (12 months) | T5 (15 months) |
|---------------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|
| **Primary outcome** |               |               |               |               |               |               |               |
| IDS-C               | x             | x             | x             | x             | x             | x             |               |
| **Secondary outcomes** |           |               |               |               |               |               |               |
| YMRS                | x             | x             | x             | x             | x             | x             |               |
| SCID-I              | x             | x             | x             | x             | x             | x             |               |
| ASRM                | x             |               |               |               |               |               |               |
| QIDS-SR             |               |               |               |               |               |               |               |
| STAI                |               |               | x             | x             | x             | x             | x             |
| FAST                |               |               | x             | x             | x             | x             | x             |
| MHC-SF              | x             | x             | x             | x             | x             | x             | x             |
| FFMQ                |               |               |               |               |               |               |               |
| SCS-SF              |               |               |               |               |               |               |               |
| RPA-NL              |               |               | x             | x             | x             | x             | x             |
| RPS-EXT             |               |               |               |               |               |               |               |
| **Cost-effectiveness** |           |               |               |               |               |               |               |
| EQ-SD-5L            | x             |               | x             | x             | x             | x             | x             |
| TiP-P               | x             | x             | x             | x             | x             | x             |               |
The brooding subscale of the extended version of the Ruminative Response Scale (RRS-EXT) [48] will be used to assess levels of brooding, also known as rumination. The brooding subscale consists of five items and has been shown to have adequate psychometric properties [48].

The Responses to Positive Affect Questionnaire - Dutch Version (RPA-NL) [9] will be used to assess responses to positive affective states. The RPA-NL is a 17-item self-report questionnaire consisting of three subscales, including: 1) dampening of positive affect; 2) self-focused positive rumination; and 3) emotion-focused positive rumination. The psychometric properties of the English [9] and Dutch [10] version of the RPA have been shown to be adequate.

The Five Facet Mindfulness Questionnaire - Short Form (FFMQ-SF) [49], a 24-item questionnaire, will be used to assess different aspects of mindfulness, including: 1) observing, 2) describing, 3) acting with awareness, 4) non-judging of inner experiences, and 5) non-reactivity to inner experiences. The psychometric properties of the FFMQ-SF have been shown to be adequate [49].

The Self Compassion Scale – Short form (SCS-SF) [50] will be used to assess levels of self-compassion. The SCS-SF is a 12-item measure that consists of three concepts that are related to self-compassion, including: 1) self-kindness versus self-judgment; 2) common humanity versus isolation; and 3) mindfulness versus over-identification. The psychometric properties of the SCS-SF have been shown to be adequate [50].

Cost-effectiveness
The EQ-5D-5 L [51] will be used to measure the Quality of Life and the Quality Adjusted Life Years. The EQ-5D-5 L consists of five dimensions, including: 1) mobility; 2) self-care; 3) usual activities; 4) pain/discomfort; and 5) anxiety/depression. The psychometric properties of the EQ-5D-5 L have been shown to be adequate [52].

The Trimbos/iMTA questionnaire for costs associated with psychiatric illness (TiC-P) [53] will be used to assess recourse use, such as use of care, medication, and illness related to work. It measures both direct costs, i.e. care consumption of people suffering from psychiatric illness, and indirect costs, i.e. costs associated with production loss. The psychometric properties of the TiC-P have been shown to be adequate [54].

Adherence
Participants in the MBCT + TAU condition will be asked to daily document adherence to mindfulness practice. For this purpose, a calendar was designed on which participants will be asked to fill out the number of minutes daily spent on formal and informal mindfulness practices during the intervention. During follow-up, adherence will be retrospectively determined using a short questionnaire, asking which mindfulness exercises they still practice, how often and for how long. Participants in both conditions will be asked to document their medication adherence as well, using the Prospective Life Chart, self-report [41].

Safety monitoring
In accordance with Good Clinical Practice guidelines, (serious) adverse events, both related and unrelated to the study, will be reported. During follow-up assessments, participants will be explicitly asked whether they have experienced any undesirable (medical) incidents during the study period. The occurrence, intensity and duration of these (serious) adverse events will be documented carefully. Furthermore, participants in the MBCT + TAU condition will be asked to daily document any (serious) adverse reactions ((S)AR) they might experience in response to mindfulness practice during the MBCT intervention. For this purpose, a log was designed on which twelve of the most likely (S)AR related to mindfulness practice for bipolar patients are documented. These (S)AR are inspired by earlier studies on adverse effects in meditation [55–57] and include the following: 1) re-experiencing of traumatic memories; 2) overwhelming or uncontrollable feelings of depression; 3) uncontrollable feelings of happiness or grandiosity; 4) uncontrollable feelings of irritability; 5) sudden (increase) of anxiety or panic; 6) feelings of derealization; 7) feelings of depersonalization; 8) feelings of distrust to others; 9) feelings of doubt towards the self; 10) visual hallucinations; 11) auditory hallucinations; and 12) unusual physical sensations. Participants will be asked to indicate how often they experienced certain (S)AR, whether they consider these reactions to be causally related to meditation, the intensity of these (S)AR in a scale from 1 to 10 (were 1 = low intensity and 10 = high intensity), and how they reacted in response to this (S)AR. In the long-term, if not reported spontaneously, (S)AR will be retrospectively determined during qualitative interviews.

Statistical analysis
Sample size calculation
The sample size calculation was based on the estimated change in depressive symptom severity from pre- to post-intervention, as reported in a similar study about the efficacy of MBCT in recurrent depression conducted at the Radboud University Medical Centre [24]. This study found an effect size of 0.5 for reduction of depressive symptoms in people with recurrent (unipolar) depression, who were partly in remission (n = 124), or partly currently depressed (n = 58). Based on a two-sided
recruit 160 patients (intervention group $n$ of 40% loss to follow-up, the current study will intend to recruit 160 patients (intervention group $n = 80$, control group $n = 80$).

**Statistical analysis**

All data will be analyzed and reported according to the CONSORT guidelines [58], using intention-to-treat and per-protocol analyses. Inadvertently unequally distributed baseline parameters between the conditions will be included as covariates. Assumptions of normality will be checked and, in case of lack of normality, the bootstrapping procedure will be used to account for this problem [59]. Sensitivity analyses will be conducted with different scenarios of imputed data sets to examine the influence of missing data on the pattern of outcomes.

Primary analysis will be aimed at comparing depressive symptom severity at three months after baseline between MBCT + TAU and TAU. In order to investigate consolidation of treatment effect, outcomes will be assessed at 6, 9, 12, and 15 months follow-up. Secondary analyses will be aimed at comparing the treatment effects of MBCT + TAU versus TAU on (hypo)manic and anxiety symptom severity, relapse rates, and overall functioning and positive mental health, post-intervention and up to 15 months follow-up. Multilevel analysis will be used to account for the cluster-randomized design and, therefore, the hierarchical structure of the data, with outcome variables at pre- and postmeasurements at the lowest level, nested within individuals, nested within treatment groups (in the intervention condition), and nested within condition (MBCT + TAU versus TAU). Mediation analysis will be conducted to investigate whether possible clinical effects of MBCT in primary outcome measures are mediated by rumination on positive and negative affect, mindfulness skills, and self-compassion [60]. Additional analyses will be performed within subgroups who suffered <12 or ≥12 mood episodes, and within subgroups with and without a current depressive episode.

The economic evaluation will be based on the general principles of a cost-utility, cost-effectiveness, and budget-impact analysis, comparing MBCT + TAU versus TAU. Primary outcomes of the economic evaluation will be quality adjusted life years (QALYs), treatment response (scores on IDS-C), and both direct and indirect costs [61]. The incremental cost-effectiveness ratio (ICER) will be computed using non-parametric bootstrap methods to account for skewness of the cost-data. The cost-effectiveness ratio will be stated in terms of costs per outcome rate (IDS-C), while the cost-utility ratio will focus on the cost per QALY gained. The budget impact analysis (BIA) will be used as outlined by the IPSOR Task Group [62, 63] to assess how health care budgets change when MBCT is offered over a range of implementation levels. The BIA will be conducted from various perspectives, including: 1) the societal perspective (i.e. productivity loss); 2) the perspective of the public purse; and 3) the perspective of the health care insurer. In each perspective different scenarios will be assessed, in which the intervention is offered to 40, 60, and 80% of the target group, and an extreme scenario in which 100% of the target group will be receiving MBCT interventions. These scenarios will be compared with a base-case scenario where 0% of the target group is offered MBCT (reflecting TAU). The BIA will be based on a health-economic simulation excel model, based on modeling techniques outlined by Briggs, Claxton, and Sculpher [64], and following IPSOR modeling guidelines [65]. The BIA will be conducted according to the Dutch guidelines [66], taking into account the complexity and dynamics of clinical practice and specific characteristics of the Dutch health care system.

**Discussion**

The current trial will be the first properly powered, multicenter, randomized controlled trial of MBCT for BD in the Netherlands and the second world-wide. It will provide high-level evidence of the relative long-term effectiveness of MBCT + TAU compared to TAU alone by including follow-up measurements up to 15 months on keeping close track of treatment adherence and occurrence of (serious) adverse reactions. The study will be conducted in five specialized clinics for bipolar disorders in order to enhance generalizability. From a societal perspective, the current trial will assess whether adding MBCT to TAU is cost-effective. This study will provide valuable insight into the accessibility and (cost-) effectiveness of MBCT in terms of clinician-rated and self-rated symptoms of BD, relapse rates, positive mental health, and overall functioning. Furthermore, this study might elucidate in which stage(s) of the illness MBCT might be helpful in relieving residual mood symptoms.

**Abbreviations**

SAR: (serious) adverse reaction; BIA: Budget impact analysis; CBT: Cognitive behavioral therapy; CHIME: Comprehensive inventory of mindfulness experience; DSM-5: Diagnostic and statistical manual of mental disorders – 5th edition; FAST: Functioning Assessment Short Test; ICER: Incremental cost-effectiveness ratio; MBCT: Mindfulness-Based Cognitive Therapy; MBI-TAC: Mindfulness-Based Interventions – Teacher Assessment Criteria; MHC-SF: Mental Health Continuum- Short Form; OASIS: Overall anxiety severity and impairment scale; QALY: Quality adjusted life years; SCID-I: Structured Clinical Interview for DSM-IV Axis I Disorders; SCS-SF: Self-Compassion Scale – Short Form; STAI: State/Trait Anxiety Inventory; TAU: Treatment as usual; TiC-P: Trimbos/IMTA questionnaire for costs associated with psychiatric illness; YMRS: Young Mania Rating Scale.
Acknowledgements
Not applicable.

Funding
This study is externally funded by a grant from ZonMw, the Netherlands Organization for Health Research and Development (Grant Number: 843002803) awarded to prof. dr. A. E. M. Spekens and dr. M. J. Huljbers. The funding agency will have no role in data collection, management, analysis, interpretation of data; writing of the report; or the decision to submit the report for publication.

Availability of data and materials
Not applicable.

Authors’ contributions
All authors contributed to the design of the study. AES is the principal investigator. IH drafted this paper, which was supplemented by all other authors. IH, MH, RK, MLvB, ER, and AS will be involved in recruiting participants. IH will be responsible for the logistics and data collection. SE contributed to the design of cost-effectiveness study and MW contributed to the implementation strategy. All authors have read and approved the final paper.

Ethics approval and consent to participate
The study protocol has been approved by the ethical review board CMO Arnhem – Nijmegen and is registered under number NL63319.091.17. Both verbal and written consent to participate will be obtained.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Psychiatry, Centre for Mindfulness, Radboud University Medical Centre, Postbus 9101, 6500, HB, Nijmegen, The Netherlands.
2Donders Institute for Brain, Cognition and Behaviour, Radboud University, Nijmegen, The Netherlands.
3Department of Mood Disorders, Pro Persona, Mental Health Care, Tarweweg 2, 6534, AM, Nijmegen, The Netherlands.
4Atrecht, Institute for Mental Health Care, Outpatient clinic for Bipolar Disorders, Nieuwe Houtenseweg 12, 5524, SH, Utrecht, the Netherlands.
5Dementie Mental Health, Center for Bipolar Disorders, Pijutersbaan 3, 7411, GT, Deventer, The Netherlands.
6Trimbos-instituut, Postbus 725, 3500, AS, Utrecht, the Netherlands.
7Radboud University Medical Centre, Institute for Quality in Health Care, Postbus 9101, 6500, HB, Nijmegen, the Netherlands.
8Department of Psychiatry, Amsterdam UMC, Vrije Universiteit, Amsterdam Public Health Research Institute, Oldenaller 1, 1081, HJ, Amsterdam, the Netherlands.

Received: 24 October 2018 Accepted: 11 April 2019

Published online: 30 April 2019

References
1. de Graaf R, Ten Have M, van Gool C, van Dorselaer S. Prevalence of mental disorders and trends from 1996 to 2009. Results from the Netherlands mental health survey and incidence Study-2. Soc Psychiatry Psychiatr Epidemiol. 2012;47(2):203–13.
2. Dilsaver SC. An estimate of the minimum economic burden of bipolar I and II disorders in the United States. 2009. J Affect Disord. 2011;129(1–3):79–83.
3. McClure P, Dhanasiri S, Patel A, Knapp M, Lawton-Smith S. Paying the price. In: The cost of mental health care in England to 2026: King’s Fund. 2008.
4. Pini S, de Queiroz V, Pagnin D, Pezawas L, Angst J, Cassano GB, Wittenchen H-U. Prevalence and burden of bipolar disorders in European countries. Eur Neuropsychopharmacol. 2005;15(4):425–34.
5. Judd LL, Akiskal HS. Depressive episodes and symptoms dominate the longitudinal course of bipolar disorder. Curr Psychiatry Rep. 2003;5(6):417–8.
6. Judd LL, Akiskal HS, Schettler PJ, Endicott J, Maser J. Solomon DA, Leon AC, Rice JA, Keller MB. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 2002;59(6):530–7.
7. Johnson SL, McKenzie G, McMurtrh S. Ruminative responses to negative and positive affect among students diagnosed with bipolar disorder and major depressive disorder. Cogn Ther Res. 2008;32(5):702–13.
8. Hassen I, Regge EJ, Schut D, Boelen PA. Ruminative and dampening responses to positive affect in bipolar disorder and major depressive disorder. Compr Psychiatry. 2018;85:72–7.
9. Feldman GC, Joomrn I, Johnson SL. Responses to positive affect: a self-report measure of rumination and dampening. Cogn Ther Res. 2008;32(4):507–25.
10. Faes F, Daems K, Feldman GC, Johnson SL, van Gucht D. A psychometric evaluation of the dutch version of the responses to positive affect questionnaire. Psicologica Belgica. 2009;49(4):293–310.
11. Judd LL, Schettler PJ, Akiskal HS, Maser J, Coryell W, Solomon D, Endicott J, Keller M. Long-term symptomatic status of bipolar I vs. bipolar II disorders. J Clin Psychiatry. 2003;64(2):127–37.
12. Perkins RH, Ostacher MJ, Patel J, Marangell LB, Zhang H, Wisciewski SR, Ketter TA, Miklowitz DJ, Otto MW, Gyalai L. Predictors of recurrence in bipolar disorder: primary outcomes from the systemic treatment enhancement program for bipolar disorder (STEP-BD). Am J Psychiatry. 2006;163(2):217–24.
13. Giltin MJ, Swendsen J, Heller TL, Hammen C. Relapse and impairment in bipolar disorder. Am J Psychiatry. 1995;152(11):1635.
14. Gómez-Rojas L, Garpaegu M, Ayuso-Mateos J, GutiéErez-Ariza JA, Ruiz-Vegulla M, Jurado D. Quality of life in bipolar disorder patients: a comparison with a general population sample. Bipolar Disord. 2008;10(5):625–34.
15. Vieta E, Colom F. Psychological interventions in bipolar disorder: from wishful thinking to an evidence-based approach. Acta Psychiatr Scand. 2004;110(4):34–8.
16. Oud M, Mayo-Wilson E, Braidwood R, Schulte P, Jones SH, Morris R, Kupka R, Cuipers P, Kendall T. Psychological interventions for adults with bipolar disorder: systematic review and meta-analysis. Br J Psychiatry. 2016;208(5):213–22.
17. Scott J, Garland A, Moorhead S. A pilot study of cognitive therapy in bipolar disorders. Psychol Med. 2001;31(3):459–67.
18. Scott J, Paykel E, Morriss R, Bentall R, Kinderman P, Johnson T, Abbott R, Hayhurst H. Cognitive-behavioural therapy for severe and recurrent bipolar disorders. Br J Psychiatry. 2006;188(4):313–20.
19. Kupka RW, Goossens P, van Bendegem M, Daemen P, Daggvoorade T, Daniels M, Dol A, van Duij D, Hille M, Hoogelander A. Multidisciplinary richtlijn bipolaire stoornissen (derde herziene versie). Utrecht: De Tijdstroom. 2015.
20. Segal ZV, Williams JMG, Teasdale JD. Mindfulness-based cognitive therapy for depression, 2nd ed. New York: Guildford Press; 2012.
21. Deckenbach T, Holzé B, Eisner L, Lazar SW, Nierenberg AA. Mindfulness-based cognitive therapy for bipolar disorder. New York: The Guildford Press; 2014.
22. Khoury B, Lecomte T, Fortin G, Masse M, Therien P, Bouchard V, Chapleau M, Gueroux P, van den Bussche H, Morgenstern K. Mindfulness-based therapy: a comprehensive meta-analysis. Clin Psychol Rev. 2013;33(6):763–71.
23. Yueken W, Warren F, Taylor RS, Whalley B, Crane C, Bondolfi G, Hayes R, Huljbers MA, Herwitz S, et al. Efficacy and moderators of mindfulness-based cognitive therapy (MBCT) in prevention of depressive relapse: an individual patient data meta-analysis from randomized trials. JAMA Psychiatry. 2016;73(9):565–74.
24. van Aalderen JR, Donders AR, Giommi F, Spinopoulos P, Barendrecht HP, Speckens AE. The efficacy of mindfulness-based cognitive therapy in recurrent depressed patients with and without a current depressive episode: a randomized controlled trial. Psychol Med. 2012;42(5):989–1001.
25. Strauss C, Cavagnil O, Oliver A, Pettman D. Mindfulness-based interventions for people diagnosed with a current episode of an anxiety or depressive disorder: a meta-analysis of randomised controlled trials. PLoS One. 2014;9(3):1–13.
26. Miklowitz DJ, Alattar Y, Goodwin GM, Geddes JR, Fennell MJ, Mardijan S, Hauser M, Williams JMK. A pilot study of mindfulness-based cognitive therapy for bipolar disorder. Int Assoc Cogn Psychother. 2009;24(4):373–82.
27. Williams JBW, Alattar Y, Crane C, Banhofer T, Fennell MJ, Duggan DS, Hepburn S, Goodwin GM. Mindfulness-based cognitive therapy (MBCT) in bipolar disorder: preliminary evaluation of immediate effects on between-episode functioning. J Affect Disord. 2008;107(1–3):275–9.
28. Deckenbach T, Holzel BK, Eisner LR, Stange JP, Peckham AD, Dougherty DD, Rauch SL, Lazar S, Nierenberg AA. Mindfulness-based cognitive therapy for nonremitted patients with bipolar disorder. CNS Neurosci Ther. 2012;18(2):133–41.
29. Weber B, Jermann F, Gex-Fabry M, Nallet A, Bondolfi G, Aubry JM. Mindfulness-based cognitive therapy for bipolar disorder: a feasibility trial. Eur Psychiatry. 2010;25(6):334–7.

30. Perich T, Manicavasagar V, Mitchell PB, Ball JR, Hadzi-Pavlovic D. A randomized controlled trial of mindfulness-based cognitive therapy for bipolar disorder. Acta Psychiatr Scand. 2013;127(5):333–43.

31. Gu J, Strauss C, Bond R, Cavanagh K. How do mindfulness-based cognitive therapy and mindfulness-based stress reduction improve mental health and wellbeing? A systematic review and meta-analysis of mediatiol. Clin Psychol Rev. 2015;37:1–12.

32. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5®). 5th ed. Arlington, VA: American Psychiatric Association; 2013.

33. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured clinical interview for the DSM-IV Axis I disorders (SCID-I). New York: Biometric Research; 1996.

34. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133(5):295–301.

35. Good practice guidance for teaching mindfulness-based courses [http://www.bangor.ac.uk/mindfulness/documents/MBA%20Teaching%20GP%20Guidance%202010.pdf].

36. Crane RS, Kuyken W, Williams JM, Hastings RP, Cooper L, Fennell MJV. Competence in teaching mindfulness-based courses: concepts, development and assessment. Mindfulness. 2012;3:76–84.

37. Crane RS, Eames C, Kuyken W, Hastings RP, Williams JM, Bartley T, Evans A, Silverton S, Soulsby JS, Surawczy C. Development and validation of the mindfulness-based interventions–teaching assessment criteria (MBITAC). Assessment. 2013;20(6):681–8.

38. Akkerhuis GW, Vertaling IDS, Utrecht, H.C. Rümkra Grop; 1997.

39. Trivedi MH, Rush AJ, Ibrahim HM, Carmody TJ, Biggs MM, Suppes T, Crismon ML, Shores-Wilson K, Toprac MG, Denny DH, et al. The Inventory of Depressive Symptomatology (IDS-C) and self-report (IDS-SR), and the quick inventory of depressive symptomatology, clinician rating (QIDS-C) and self-report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. Psychol Med. 2004;34(1):73–82.

40. Løbøstet J, Leurgans M, Amitz A. Inter-rater reliability of the structured clinical interview for DSM-IV Axis I disorders (SCID-I) and Axis II disorders (SCID-II). Clin Psychol Psychother. 2011;18(1):75–9.

41. Kupla RW, Akkerhuis GW, Nolten WA, Honig A. De leef-karmethodo voor de manisch-depressieve stoomis. Tijdschrift voor Psychiatrie. 1997;30(3):232–9.

42. Altman G, Hedeker D, Peterson JL, Davis JM. The Altman self-rating mania scale. Soc Biol Psychiatry. 1997;42:948–55.

43. Akkerhuis GW, Vertaling IDS, Utrecht, H.C. Rümkra Grop; 1997.

44. Akkerhuis GW, Vertaling IDS, Utrecht, H.C. Rümkra Grop; 1997.

45. Crane RS, Kuyken W, Williams JM, Hastings RP, Cooper L, Fennell MJV. Competence in teaching mindfulness-based courses: concepts, development and assessment. Mindfulness. 2012;3:76–84.

46. Crane RS, Eames C, Kuyken W, Hastings RP, Williams JM, Bartley T, Evans A, Silverton S, Soulsby JS, Surawczy C. Development and validation of the mindfulness-based interventions–teaching assessment criteria (MBITAC). Assessment. 2013;20(6):681–8.

47. Akkerhuis GW, Vertaling IDS, Utrecht, H.C. Rümkra Grop; 1997.

48. Trivedi MH, Rush AJ, Ibrahim HM, Carmody TJ, Biggs MM, Suppes T, Crismon ML, Shores-Wilson K, Toprac MG, Denny DH, et al. The Inventory of Depressive Symptomatology (IDS-C) and self-report (IDS-SR), and the quick inventory of depressive symptomatology, clinician rating (QIDS-C) and self-report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. Psychol Med. 2004;34(1):73–82.

49. Løbøstet J, Leurgans M, Amitz A. Inter-rater reliability of the structured clinical interview for DSM-IV Axis I disorders (SCID-I) and Axis II disorders (SCID-II). Clin Psychol Psychother. 2011;18(1):75–9.

50. Kupla RW, Akkerhuis GW, Nolten WA, Honig A. De leef-karmethodo voor de manisch-depressieve stoomis. Tijdschrift voor Psychiatrie. 1997;30(3):232–9.

51. Altman G, Hedeker D, Peterson JL, Davis JM. The Altman self-rating mania scale. Soc Biol Psychiatry. 1997;42:948–55.

52. Akkerhuis GW, Vertaling IDS, Utrecht, H.C. Rümkra Grop; 1997.

53. Hakkaart VR, L, Van Straten A, Donker M, Tiemens B: Trimbos/iMTA questionnaire for costs associated with psychiatric illness (TiC-P), Institute for Medical Technology Assessment, Erasmus University Rotterdam Trimbos 2002.

54. Bouwmans C, de Jong K, Timman R, Zijlstra-Vlastuin M, van der Feltz-Cornells C, Swan Tari S, Hakkaart-van Roijen L. Feasibility, reliability and validity of a questionnaire on healthcare consumption and productivity loss in patients with a psychiatric disorder (TiC-P). BMC Health Serv Res. 2012;13:1–9.

55. Lindahl JR, Fisher NE, Cooper DJ, Rosen RK, Britton WB. The varieties of contemplative experience: a mixed-methods study of meditation-related challenges in Western Buddhists. PLoS One. 2012;7(5):e17629.

56. Dobkin PL, Irving JA, Amir S. For whom may participation in a mindfulness-based stress reduction program be contraindicated? Mindfulness. 2012;3:44–50.

57. Shapiro DH. Adverse effects of meditation: a preliminary investigation of long-term meditators. Int J Psychosom. 1992;39(1–4):62–7.

58. Schulz KE, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Biomedical Central Med. 2010;18(1):1–9.

59. Efron B, Tishbreni RJ. An introduction to the bootstrap. New York: Chapman & Hall; 1993.

60. Preacher KJ, Hayes AF. Asymptotic and resampling strategies for assessing and comparing indirect effects in multiple mediator models. Behav Res Methods. 2008;40(3):879–91.

61. Tan SS, Bouwmans-Frijters CAM, Hakkaart-van Roijen L. Handleiding voor kostenonderzoek: methoden en referentiepunten voor economische evaluaties in de gezondheidszorg. Tijdschrift voor gezondheidswetenschappen. 2012;20(6):367–72.

62. Mauskopf JA, Sullivan SD, Annemans L, Caro J, Mullins CD, Nuijten M, Orlewska E, Watkins J, Trueman P. Principles of good practice for budget impact analysis: report of the ISPOR task force on good research practices—budget impact analysis. Value Health. 2007;10(5):336–47.

63. Sullivan SD, Mauskopf JA, Augustovski F, Caro J, Lee KM, Minchin M, Orlewska E, Penna P, Barrios J, Shau W. Budget impact analysis—principles of good practice: report of the ISPOR 2012 budget impact analysis good practice II task force. Value Health. 2014;17(5):135–145.

64. Briggs AH, Claxton K, Sculpher MJ. Decision modelling for health economic evaluation. Oxford: Handbooks in Health Economics; 2006.

65. Caro JJ, Briggs AH, Sabett U, Kuntz KM. ISPOR-SMDM modeling good research practices task force. Modeling good research practices—overview: a report of the ISPOR-SMDM modeling good research practices task force–1. Value Health. 2012;15(6):796–803.

66. Format Budget Impact Analyse [https://www.zorginstituutnederland.nl/publicaties/publicatie/2016/04/06/format-budget-impact-analysis-gvs-voorcorn-kostenconsequentieraming].